$0.72 Earnings Per Share Expected for Repligen Co. (NASDAQ:RGEN) This Quarter

Analysts expect Repligen Co. (NASDAQ:RGENGet Rating) to report earnings per share of $0.72 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.76 and the lowest estimate coming in at $0.66. Repligen reported earnings of $0.68 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 5.9%. The firm is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Repligen will report full-year earnings of $3.26 per share for the current fiscal year, with EPS estimates ranging from $3.24 to $3.28. For the next fiscal year, analysts forecast that the company will post earnings of $3.83 per share, with EPS estimates ranging from $3.60 to $4.12. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Repligen.

Repligen (NASDAQ:RGENGet Rating) last issued its earnings results on Thursday, February 17th. The biotechnology company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.16. Repligen had a net margin of 19.13% and a return on equity of 10.58%. The company had revenue of $186.52 million for the quarter, compared to analyst estimates of $178.27 million. During the same period in the prior year, the business posted $0.52 earnings per share. The firm’s revenue for the quarter was up 71.7% compared to the same quarter last year.

Several brokerages have weighed in on RGEN. StockNews.com began coverage on shares of Repligen in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating and set a $190.00 price target on the stock. in a research report on Monday, February 21st. Finally, SVB Leerink lowered their price target on shares of Repligen from $275.00 to $250.00 and set an “outperform” rating on the stock in a research report on Friday, February 18th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $291.63.

In related news, Director Thomas F. Ryan, Jr. sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $198.03, for a total transaction of $396,060.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. HM Payson & Co. purchased a new position in shares of Repligen during the fourth quarter valued at approximately $26,000. CENTRAL TRUST Co raised its stake in Repligen by 531.3% during the third quarter. CENTRAL TRUST Co now owns 101 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 85 shares during the period. Confluence Wealth Services Inc. acquired a new position in shares of Repligen in the 4th quarter valued at $27,000. Allworth Financial LP grew its stake in shares of Repligen by 51.4% during the 3rd quarter. Allworth Financial LP now owns 106 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 36 shares during the period. Finally, Simon Quick Advisors LLC increased its holdings in shares of Repligen by 68.4% during the 3rd quarter. Simon Quick Advisors LLC now owns 128 shares of the biotechnology company’s stock worth $36,000 after buying an additional 52 shares during the last quarter. 86.25% of the stock is currently owned by institutional investors and hedge funds.

RGEN traded down $10.88 on Friday, hitting $169.98. 402,980 shares of the company were exchanged, compared to its average volume of 409,786. The business’s fifty day moving average is $184.42 and its 200 day moving average is $230.93. Repligen has a fifty-two week low of $156.27 and a fifty-two week high of $327.32. The firm has a market capitalization of $9.40 billion, a P/E ratio of 75.88 and a beta of 0.90.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.